Rights and permissions
About this article
Cite this article
ATG vs muromonab-CD3 for induction therapy in renal transplant. Pharmacoecon. Outcomes News 40, 9 (1995). https://doi.org/10.1007/BF03309880
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03309880